Medtronic plc Stock
Medtronic plc Stock
Pros and Cons of Medtronic plc in the next few years
Pros
Cons
Performance of Medtronic plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medtronic plc | 1.670% | 1.230% | 6.406% | -4.041% | -9.703% | -7.214% | -33.080% |
| Dexcom Inc. | 4.970% | 14.921% | 19.472% | 5.663% | 26.308% | -34.822% | -33.395% |
| Baxter International | 7.500% | 15.156% | 18.961% | 19.507% | 39.209% | -44.615% | -65.225% |
| Idexx Laboratories Inc. | 3.490% | 1.232% | 2.604% | 4.642% | -17.089% | 0.041% | -15.292% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance at Medtronic's financials, the company appears to be a strong player in the Healthcare Equipment & Supplies sector. Over the years, Medtronic has demonstrated relatively stable financial performance, which is a desirable attribute for a healthcare company. However, more in-depth analysis is needed to better understand the pros and cons of its financial situation.
Revenue Growth: Medtronic's total revenue has experienced consistent growth over the last three years as seen in the yearly income statements. In 2020, the company recorded total revenue of $28.913 billion which increased to $30.117 billion in 2021, and further to $31.686 billion in 2022.
Increasing Gross Profit: Medtronic has seen a rise in its gross profit, from $19.489 billion in 2020 to $19.634 billion in 2021, and eventually $21.541 billion in 2022. This implies that the company is becoming more efficient in its manufacturing and supply chain activities, which is a good sign for potential investors.
Comments
News
Proto Labs Q2 Earnings Call Highlights
Key Points
- Interested in Proto Labs, Inc.? Here are five stocks we like better.
- Record revenue and stronger profitability: Proto Labs reported Q2 revenue of $149.3 million, up 10.2% year over
This Stock Is Knocking on the Door of the Dividend Kings -- and Wall Street Thinks It Has Room to Run
Medtronic (NYSE: MDT), one of the world's largest medical device makers, was once a reliable blue chip dividend stock. But over the past five years, its stock has declined 33%. Even after including
3 Stocks I'm Not Selling No Matter What the Market Does
The stock market hasn't endured a deep bear market since the Great Recession. There have been corrections and bear markets since that point, but they have been brief affairs. With the market near